SEC Form 4 · accession 0001232524-18-000059
Jazz Pharmaceuticals plc · JAZZ
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matthew P. Young
Officer — EVP & CFO
Period of report
Mar 5, 2018
Accepted (ET)
Mar 7, 2018 · 4:10 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001232524
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Mar 5, 2018 | F | 1,348 | $143.39 | D | 41,017 | D | |
| Ordinary SharesF3 | Mar 6, 2018 | S | 800 | $142.06 | D | 40,217 | D | |
| Ordinary SharesF4 | Mar 6, 2018 | S | 352 | $143.0406 | D | 39,865 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units.
- F2This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- F3Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $141.4500 to $142.4200. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F4Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $142.6400 to $143.4400. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.